Stelara vs. Wezlana: Understanding Ustekinumab Biosimilars

At a Glance

• Wezlana (ustekinumab-auub) is an FDA-approved biosimilar designated as interchangeable with Stelara (ustekinumab).
• Both medications inhibit interleukin-12 (IL-12) and interleukin-23 (IL-23) proteins to stop chronic autoimmune inflammation in skin and gut tissue.
• Because of its interchangeable status, pharmacists in many U.S. states can automatically substitute Stelara with Wezlana at the pharmacy counter.
• Oral targeted agents like Otezla or Xeljanz provide non-biologic alternatives for patients managing psoriatic disease or colitis.

Understanding Stelara vs. Wezlana

Both Stelara and Wezlana contain ustekinumab, a human IgG1k monoclonal antibody. In healthy bodies, the immune system uses chemical messengers called cytokines to fight off infections. In autoimmune disorders, overactive IL-12 and IL-23 cytokines trigger persistent inflammatory cascades that attack healthy skin cells or gut mucosal linings.

By binding to the p40 subunit shared by both IL-12 and IL-23, ustekinumab blocks these signaling pathways. Physicians frequently prescribe ustekinumab therapies to treat severe plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn disease, and ulcerative colitis.

What Does "Interchangeable Biosimilar" Mean?

Wezlana is not only a biosimilar to Stelara; it also earned the FDA’s formal interchangeability designation. This means clinical studies proved that patients can switch back and forth between Stelara and Wezlana without any loss of efficacy, increase in side effects, or immune reactivity. Depending on state prescription laws, your pharmacy may substitute Stelara with Wezlana automatically to lower your out-of-pocket costs.

Insurance & Savings Note: The approval of interchangeable biosimilars like Wezlana creates competition that reduces drug costs for patients managing chronic conditions while maintaining identical clinical standards.

Comparing Key Features

Dosing Schedules and Administration

Transitioning from Stelara to Wezlana requires no adjustment to your treatment calendar or dosage amounts:

• Psoriasis & Psoriatic Arthritis: Administered as a subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
• Crohn’s Disease & Ulcerative Colitis: Starts with a single weight-based intravenous (IV) induction dose administered in a clinic, followed by regular subcutaneous maintenance injections every 8 weeks starting at Week 8.
• Device Mechanics: Wezlana is packaged in prefilled syringes designed for subcutaneous self-injection, following storage and handling protocols identical to Stelara.

Safety Warning: Ustekinumab suppresses immune response pathways, increasing susceptibility to serious bacterial, fungal, or viral infections. Patients should be evaluated for latent tuberculosis (TB) prior to initiating therapy and should avoid receiving live vaccines while on active treatment.

Alternative Treatment Pathways

Patients who do not achieve full disease control with IL-12/23 inhibitors or who prefer oral therapies can explore complementary care options in our catalog:

• Oral PDE4 Inhibitors: Non-biologic daily options like Otezla (apremilast) effectively manage plaque psoriasis and joint stiffness without requiring injections.
• Targeted Oral Immunomodulators: Small-molecule treatments like Xeljanz (tofacitinib) provide targeted relief for inflammatory bowel disease and psoriatic arthritis.
• Systemic Maintenance Agents: Traditional oral immunosuppressants such as Imuran (azathioprine) or Arava (leflunomide) serve as baseline options for autoimmune care.

Frequently Asked Questions

Is Wezlana made by the same manufacturer as Stelara?

No. Stelara is manufactured by Janssen (Johnson & Johnson), whereas Wezlana is developed by Amgen. However, as an FDA-designated interchangeable biosimilar, Wezlana meets strict standards for structural similarity, purity, and clinical outcome.

Do I need a new prescription from my doctor to switch to Wezlana?

Because Wezlana holds FDA interchangeable status, pharmacists in many U.S. states can substitute it for Stelara without requiring a new doctor's prescription, provided your healthcare provider has not marked "dispense as written" on your original order.

How should Wezlana be stored?

Like Stelara, Wezlana must be refrigerated between 36°F and 46°F (2°C to 8°C) in its original carton to protect it from light. Do not freeze or shake the prefilled syringe prior to administration.

Always consult your dermatologist, gastroenterologist, or rheumatologist to discuss how biosimilar options align with your personal care plan. To learn more about managing chronic digestive and skin conditions, visit our medical resource center on Inflammatory Bowel Diseases and autoimmune health guidance.